Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 283 for Lung cancer

Edit search filters
  1. Testing The Effects Of MK-3475 (Pembrolizumab) With Or Without The Usual Chemotherapy Treatment For Patients 70 Years Of Age And Older With Advanced Non-small Cell Lung Cancer

    Eau Claire, WI, La Crosse, WI

  2. A Phase 2, Multicenter, Study Of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib In Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) And BDX004 Positive Label

    Rochester, MN

  3. Pembrolizumab Plus Epacadostat Alone Or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo In Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-02/ECHO-306)

    Rochester, MN

  4. A Study To Compare The Combination Of Navlimetostat (BMS-986504) With Pembrolizumab And Chemotherapy Versus Placebo Plus Pembrolizumab And Chemotherapy In First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study Of MPDL3280A (Anti-PD-L1 Antibody) Combined With Carboplatin And Paclitaxel , And With Or Without Bevacizumab, For Patients Who Have Stage IV Non-Squamous Non-Small Cell Lung Cancer

    Jacksonville, FL

  6. A Study To Find The Recommended Dose For Further Research For VX-970 And Whole Brain Radiation Therapy To Treat Patients With Brain Metastases From Non-Small Cell Lung Cancer

    Jacksonville, FL, Rochester, MN

  7. A Study To Assess The Effectiveness, Safety, And Drug/Body Interactions Of Rovalpituzumab For Third-Line And Later Treatment Of Patients With Small Cell Lung Cancer That Has Returned Or Is Resistant To Treatment

    Rochester, MN

  8. Study Of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily And In Combination With Dabrafenib Twice Daily And Trametinib Once Daily In Combination Therapy In Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  9. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Jacksonville, FL, Rochester, MN

  10. A Study To Evaluate Tucatinib And Trastuzumab In Solid Tumors With HER2 Alterations

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer